Jun 12 |
Bio-Path files to sell 5.56M common stock, warrants
|
Jun 5 |
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
|
Jun 4 |
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
|
Jun 3 |
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
|
May 16 |
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
|
May 16 |
Q1 2024 Bio Path Holdings Inc Earnings Call
|
May 15 |
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
|
May 15 |
Bio-Path GAAP EPS of -$4.88 misses by $0.34
|
May 15 |
Bio-Path Holdings Reports First Quarter 2024 Financial Results
|
May 8 |
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
|